A recent study presented at the American Neurological Association meeting identified vascular and nonvascular risk factors associated with migraine in a population-based study in an effort to help identify targets for reducing migraine-related disability.
A study presented at the American Neurological Association meeting, held October 13-15 in St. Louis, Missouri, identified vascular and nonvascular risk factors associated with migraine in a population-based study in an effort to help identify targets for reducing migraine-related disability.
Although migraine is known to present a significant healthcare burden, stemming from both direct and indirect utilization of healthcare resources, the authors wrote that a comprehensive review of risk factors is lacking. They performed a retrospective cross-sectional analysis of the Nationwide Inpatient Sample (NIS) for years 2013 to 2014 for adults over the age of 18 hospitalized in the United States. Univariate analysis was performed using the chi-square test to identify the prevalence of the risk factors, and a multivariate survey logistic regression analysis was performed to evaluate the odds of the prevalence of risk factors; researchers also conducted a weighted analysis and removed missing age, gender, and race data.
Of the total 56,499,788 hospitalizations, 983,065 (1.74%) patients had a primary or secondary diagnosis of migraine. Younger patients (mean age 48 vs 58), females (82.1% vs 58.5%; P <.0001), white patients (76.8% vs 70.5%; P <.0001), and privately insured patients (41.1% vs 27.4%; P <.0001) had a higher prevalence of migraine.
Compared with people without migraine, patients with migraine were significantly more likely to have:
Cerebral atherosclerosis, diabetes, ischemic heart disease, atrial fibrillation, and alcohol abuse were not significantly associated with migraine.
The authors said their results aid in identifying targets for migraine prevention as well as risk stratification in migraineurs.
Reference
Patel UK, Malik P, Hussain MR, et al. Vascular and non-vascular risk factors associated with migraine. Presented at: 144th Annual Meeting of the American Neurological Association; October 13-15, 2019; St. Louis, MO. Abstract S199.
Prior Authorization Requirements for Calcitonin Gene-Related Peptide Antagonists
April 20th 2023This quantitative and qualitative analysis highlights differences in prior authorization requirements for migraine drugs from nearly 50 managed care organizations and summarizes broad types of criteria used.
Read More
Update on Migraine Patient Care Challenges During the Pandemic
October 5th 2021Migraines plague some 35 million Americans, the majority of them women in their 30s and 40s, and disabling pain and symptoms are linked to lost productivity at work, school, and home. On this episode of Managed Care Cast, we bring you an excerpt of an interview with a headache specialist about the extra challenges for patients and providers during the pandemic.
Listen
CGRP Inhibitors: A Promising New Class of Drugs for Migraine
November 14th 2018This fall, The American Journal of Managed Care® convened a panel of experts on migraine to discuss calcitonin gene-related peptide (CGRP) inhibitors, an emerging therapy for the condition, which affects 39 million people in the United States.
Listen